Dose Escalation Trial of Denileukin Diftitox (Ontak) Post Autologous Transplantation

Inclusion Criteria

• •All patients age \> =18 who have been diagnosed with Multiple Myeloma and are scheduled for autologous peripheral blood hematopoietic stem cell transplant (AHSCT) will be screened for eligibility.
• •1. Diagnosis of Multiple Myeloma
• •2. Age \>=18 and no more than 70 years.
• •3. Able to understand and sign a consent form.
• •4. Can collect peripheral blood stem cells with a CD34+ cell dose of at least 5.0 x 106/kg. The CD34 molecule is a Cluster of Differentiation molecule present on hematopoietic stem cells.
• •5. Conditioning regimen to be high dose Melphalan at a dose of 200mg/m2.
• •6. Karnofsky Performance Score (KPS) \>60 or ECOG (Eastern Cooperative Oncology Group) performance status \<=2
• •7. Kidney function:Creatinine \<2.0 mg/dl or creatinine clearance \>50 ml/min
• •8. Heart function: Ejection fraction \>45%
• •9. Liver function tests :Serum bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST) less than 3 X upper limit of normal
• •10. Lung function tests: Forced Vital Capacity (FVC), Forced Expiratory Volume in One Second (FEV1) or Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) \>45% predicted